|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SBF2 |
Gene summary for SBF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SBF2 | Gene ID | 81846 |
| Gene name | SET binding factor 2 | |
| Gene Alias | CMT4B2 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0006914 | UniProtAcc | Q86WG5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81846 | SBF2 | CCI_1 | Human | Cervix | CC | 3.34e-07 | 7.85e-01 | 0.528 |
| 81846 | SBF2 | CCI_2 | Human | Cervix | CC | 2.86e-06 | 9.66e-01 | 0.5249 |
| 81846 | SBF2 | CCI_3 | Human | Cervix | CC | 8.80e-27 | 1.34e+00 | 0.516 |
| 81846 | SBF2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.15e-40 | -8.60e-01 | 0.0155 |
| 81846 | SBF2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.33e-09 | -6.60e-01 | -0.1808 |
| 81846 | SBF2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.68e-06 | -9.36e-01 | 0.0216 |
| 81846 | SBF2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.29e-12 | -7.96e-01 | -0.1207 |
| 81846 | SBF2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.39e-05 | -5.16e-01 | -0.1526 |
| 81846 | SBF2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.19e-22 | -6.00e-01 | -0.1464 |
| 81846 | SBF2 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.83e-04 | -3.72e-01 | -0.1001 |
| 81846 | SBF2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 4.20e-04 | -6.45e-01 | -0.1706 |
| 81846 | SBF2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.83e-06 | -8.26e-01 | -0.2061 |
| 81846 | SBF2 | HTA11_5216_2000001011 | Human | Colorectum | SER | 1.06e-07 | -9.11e-01 | -0.1462 |
| 81846 | SBF2 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.54e-05 | -6.08e-01 | -0.0842 |
| 81846 | SBF2 | HTA11_9341_2000001011 | Human | Colorectum | SER | 6.28e-05 | -9.38e-01 | -0.00410000000000005 |
| 81846 | SBF2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 8.99e-04 | -6.56e-01 | -0.0179 |
| 81846 | SBF2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.13e-19 | -6.79e-01 | 0.096 |
| 81846 | SBF2 | HTA11_4255_2000001011 | Human | Colorectum | SER | 5.52e-05 | -5.02e-01 | 0.0446 |
| 81846 | SBF2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.63e-03 | -9.09e-01 | 0.0451 |
| 81846 | SBF2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 5.92e-05 | -7.35e-01 | 0.0528 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
| GO:0043087 | Colorectum | AD | regulation of GTPase activity | 110/3918 | 348/18723 | 1.64e-06 | 5.03e-05 | 110 |
| GO:00430871 | Colorectum | SER | regulation of GTPase activity | 77/2897 | 348/18723 | 5.90e-04 | 8.07e-03 | 77 |
| GO:00430872 | Colorectum | MSS | regulation of GTPase activity | 101/3467 | 348/18723 | 1.00e-06 | 3.46e-05 | 101 |
| GO:00430873 | Colorectum | FAP | regulation of GTPase activity | 85/2622 | 348/18723 | 1.20e-07 | 7.68e-06 | 85 |
| GO:00430874 | Colorectum | CRC | regulation of GTPase activity | 69/2078 | 348/18723 | 1.11e-06 | 6.69e-05 | 69 |
| GO:00430878 | Endometrium | AEH | regulation of GTPase activity | 66/2100 | 348/18723 | 1.26e-05 | 2.77e-04 | 66 |
| GO:004308712 | Endometrium | EEC | regulation of GTPase activity | 67/2168 | 348/18723 | 1.84e-05 | 3.43e-04 | 67 |
| GO:00425524 | Esophagus | ESCC | myelination | 85/8552 | 134/18723 | 2.51e-05 | 2.13e-04 | 85 |
| GO:00072724 | Esophagus | ESCC | ensheathment of neurons | 86/8552 | 136/18723 | 2.68e-05 | 2.24e-04 | 86 |
| GO:00083664 | Esophagus | ESCC | axon ensheathment | 86/8552 | 136/18723 | 2.68e-05 | 2.24e-04 | 86 |
| GO:004308715 | Esophagus | ESCC | regulation of GTPase activity | 183/8552 | 348/18723 | 5.34e-03 | 2.00e-02 | 183 |
| GO:00430875 | Liver | NAFLD | regulation of GTPase activity | 62/1882 | 348/18723 | 5.65e-06 | 2.03e-04 | 62 |
| GO:0042552 | Liver | Cirrhotic | myelination | 46/4634 | 134/18723 | 8.04e-03 | 3.77e-02 | 46 |
| GO:0007272 | Liver | Cirrhotic | ensheathment of neurons | 46/4634 | 136/18723 | 1.08e-02 | 4.75e-02 | 46 |
| GO:0008366 | Liver | Cirrhotic | axon ensheathment | 46/4634 | 136/18723 | 1.08e-02 | 4.75e-02 | 46 |
| GO:00072721 | Liver | HCC | ensheathment of neurons | 72/7958 | 136/18723 | 8.87e-03 | 3.44e-02 | 72 |
| GO:00083661 | Liver | HCC | axon ensheathment | 72/7958 | 136/18723 | 8.87e-03 | 3.44e-02 | 72 |
| GO:00425521 | Liver | HCC | myelination | 71/7958 | 134/18723 | 9.08e-03 | 3.49e-02 | 71 |
| GO:00430876 | Lung | IAC | regulation of GTPase activity | 67/2061 | 348/18723 | 3.43e-06 | 1.44e-04 | 67 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SBF2 | SNV | Missense_Mutation | c.2084N>A | p.Pro695Gln | p.P695Q | Q86WG5 | protein_coding | tolerated(0.47) | benign(0.027) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| SBF2 | SNV | Missense_Mutation | c.1201N>C | p.Asn401His | p.N401H | Q86WG5 | protein_coding | deleterious(0.04) | probably_damaging(0.942) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR | |
| SBF2 | SNV | Missense_Mutation | novel | c.1350G>C | p.Lys450Asn | p.K450N | Q86WG5 | protein_coding | tolerated(0.08) | benign(0.056) | TCGA-AC-A2FO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | CR |
| SBF2 | SNV | Missense_Mutation | c.1536N>G | p.Asn512Lys | p.N512K | Q86WG5 | protein_coding | tolerated(0.29) | benign(0.017) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SBF2 | SNV | Missense_Mutation | novel | c.4946N>C | p.Leu1649Ser | p.L1649S | Q86WG5 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SBF2 | SNV | Missense_Mutation | rs750021823 | c.3223N>T | p.Arg1075Cys | p.R1075C | Q86WG5 | protein_coding | tolerated(0.05) | possibly_damaging(0.856) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SBF2 | SNV | Missense_Mutation | c.4024G>C | p.Glu1342Gln | p.E1342Q | Q86WG5 | protein_coding | deleterious(0.01) | possibly_damaging(0.772) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SBF2 | SNV | Missense_Mutation | c.1025N>A | p.Arg342Gln | p.R342Q | Q86WG5 | protein_coding | tolerated(0.51) | benign(0.049) | TCGA-AO-A0J3-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| SBF2 | SNV | Missense_Mutation | c.683N>T | p.Ser228Phe | p.S228F | Q86WG5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| SBF2 | SNV | Missense_Mutation | novel | c.2413N>C | p.Asp805His | p.D805H | Q86WG5 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |